Last reviewed · How we verify
Sequential therapy for 14 days — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Sequential therapy for 14 days (Sequential therapy for 14 days) — National Taiwan University Hospital. Sequential therapy for 14 days refers to a treatment regimen combining multiple therapeutic agents administered in a planned sequence over a two-week period.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Sequential therapy for 14 days TARGET | Sequential therapy for 14 days | National Taiwan University Hospital | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Sequential therapy for 14 days CI watch — RSS
- Sequential therapy for 14 days CI watch — Atom
- Sequential therapy for 14 days CI watch — JSON
- Sequential therapy for 14 days alone — RSS
Cite this brief
Drug Landscape (2026). Sequential therapy for 14 days — Competitive Intelligence Brief. https://druglandscape.com/ci/sequential-therapy-for-14-days. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing